Neoplasms, Glandular and Epithelial  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

44 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00005837: Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer

Completed
2
US, Canada
oxaliplatin
Gynecologic Oncology Group, National Cancer Institute (NCI)
Cervical Cancer
 
06/04
NCT00047177: Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Completed
2
43
US
Oxaliplatin
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
08/04
07/07
NCT00096070: Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed
2
50
US
radiation therapy, irradiation, radiotherapy, therapy, radiation, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar
National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
04/07
 
NCT00142480: Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Completed
2
8
US
Capecitabine, Oxaliplatin, Bevacizumab, Radiation therapy
Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc., Sanofi-Synthelabo, Hoffmann-La Roche
Biliary Tract Cancer, Gallbladder Adenocarcinoma
07/07
04/11
NCT00193609: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Completed
2
48
US
Oxaliplatin, Eloxatin, Capecitabine, Xeloda
SCRI Development Innovations, LLC, Roche Pharma AG, Sanofi-Synthelabo
Neoplasms, Unknown Primary
04/08
01/09
NCT00253370: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Completed
2
44
US
BAY 43-9006, Sorafenib (NSC724772), BAY 54-9085 (tosylate salt), docetaxel, Taxotere, RP 56976, NSC #628503, cisplatin, Cis-diaminedichloroplatinum, Cis-diaminedichloroplatinum (II), diaminedichloroplatinum, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875.
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
05/08
09/10
NCT00084617: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Completed
2
39
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, capecitabine, CAPE, Ro 09-1978/000, Xeloda
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
10/08
12/08
FOIB, NCT01163396: First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

Completed
2
57
Europe
Bevacizumab, Irinotecan, Oxaliplatin, 5-fluorouracil/leucovorin
Gruppo Oncologico del Nord-Ovest
Colorectal Cancer Metastatic
04/09
04/10
NCT00354887: Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater

Completed
2
31
US
Capecitabine, Xeloda, Oxaliplatin, Eloxatin
M.D. Anderson Cancer Center, Sanofi-Synthelabo
Gastrointestinal Cancer
11/09
11/09
NCT00127036: Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Terminated
2
65
US
XELOX, Oxaliplatin and Capecitabine, XELIRI, Irinotecan and Capecitabine, Bevacizumab, Avastin®
H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG
Adenocarcinoma, Colon Cancer
12/10
12/10
NCT00418093: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Terminated
2
19
US
Gemcitabine, Oxaliplatin, Bevacizumab
Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Eli Lilly and Company, Sanofi-Synthelabo, Genentech, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
01/11
10/11
NCT00313612: Oxaliplatin and Topotecan in Advance Ovarian Cancer

Terminated
2
39
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, topotecan, hycamptamine, Hycamtin, SKF S-104864-A, TOPO
National Cancer Institute (NCI)
Recurrent Ovarian Epithelial Cancer
05/11
12/12
NCT01588964: IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Completed
2
30
Europe
HIPEC, IPHC, Hypertermic intraperitoneal chemotherapy
Catholic University of the Sacred Heart
Ovarian Epithelial Cancer Recurrent
10/11
12/11
GemOx-PDT, NCT00713687 / 2008-001560-37: Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma

Withdrawn
2
0
Europe
Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®), No other names
Technische Universität München, Münchner Studienzentrum
Cholangiocarcinoma
 
12/11
FLOT3, NCT00849615: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Completed
2
252
Europe
Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid
Krankenhaus Nordwest
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
01/12
01/16
NCT00591149: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Terminated
2
16
US
Oxaliplatin, Eloxatin, Docetaxel, Taxotere, Cetuximab, Erbitux
University of Kansas Medical Center, Sanofi
Head and Neck Cancer, Carcinoma, Squamous
04/12
04/12
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Checkmark mFOLFOX6 in combination with linifanib/bevacizumab for mCRC
Jul 2014 - Jul 2014: mFOLFOX6 in combination with linifanib/bevacizumab for mCRC
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
159
US, Canada, Europe, RoW
ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil
AbbVie (prior sponsor, Abbott), Genentech, Inc.
Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
05/12
05/12
NCT00816543: Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma

Completed
2
41
RoW
DOCETAXEL, S-1, OXALIPLATIN
Sanofi
Gastric Cancer
05/12
05/12
NCT00398320: Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Completed
2
40
US
Capecitabine, Oxaliplatin, Bevacizumab
Pamela L. Kunz
Neuroendocrine Tumors
10/12
10/12
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Completed
2
29
Europe
Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy
Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L.
Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
11/12
12/14
NCT00832637: Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Terminated
2
33
US
Cisplatin, Platinol®, Erlotinib, Tarceva®, Gemcitabine, Gemzar®
New Mexico Cancer Care Alliance
Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
06/13
03/17
NCT00321685: Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

Checkmark P3 data
Jan 2013 - Jan 2013: P3 data
Completed
2
57
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
08/13
02/19
NCT00938470: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Completed
2
73
US
capecitabine, docetaxel, fluorouracil, oxaliplatin, radiation therapy, therapeutic conventional surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
12/13
03/18
NCT01229111: Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Terminated
2
14
US
cediranib maleate, AZD2171, Recentin, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU
National Cancer Institute (NCI)
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
03/14
03/14
NCT01481701: A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

Completed
2
90
Europe
Oxaliplatin, No other intervention, oxaliplatin
Jules Bordet Institute
Ovarian Carcinoma, Relapse
05/14
05/14
GRECCAR 4, NCT01333709: Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma

Completed
2
150
Europe
Induction trichemotherapy - FOLFIRINOX regimen, Early tumor response evaluation by MRI volumetry, Radiochemotherapy Cap 50, Radiochemotherapy Cap 60, Radical proctectomy with total mesorectal excision
Institut du Cancer de Montpellier - Val d'Aurelle
Locally Advanced Malignant Neoplasm, Rectal Carcinoma
09/14
09/14
NCT01558011: Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study

Terminated
2
51
RoW
Capecitabine, Oxaliplatin, Docetaxel, Capecitabine (Xeloda○R), company: Roche, Oxaliplatin (Eloxatin○R, company: Sanofi-Avantis, Docetaxel (Taxotere○R, company: Sanofi-Avantis
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital, Mackay Memorial Hospital, National Cheng-Kung University Hospital
Gastric Adenocarcinoma
10/14
12/15
NCT00609336: Perioperative Therapy for Resectable Pancreatic Cancer

Completed
2
35
US
gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, docetaxel, RP 56976, Taxotere, TXT, capecitabine, CAPE, Ro 09-1978/000, Xeloda, intensity-modulated radiation therapy, IMRT, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pancreatic surgical procedure, pancreatic surgery, therapeutic conventional surgery, laboratory biomarker analysis
University of Washington, National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
11/14
12/16
NCT02344810: C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Withdrawn
2
0
US
c-Met inhibitor AMG 337, AMG 337, AMG337, placebo, PLCB, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, pharmacological study, pharmacological studies, laboratory biomarker analysis
Eastern Cooperative Oncology Group, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
03/15
 
Prodige20, NCT01900717: Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma

Completed
2
102
Europe
LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified, LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
Centre Hospitalier Universitaire Dijon
Metastatic Colorectal Adenocarcinoma
05/15
03/16
SWOG-S1115, NCT01658943: Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
137
US
Akt Inhibitor MK2206, MK2206, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin, Oxaliplatin, 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244
National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
06/15
06/15
NCT01932580: Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma

Completed
2
10
Canada
FLOT (5-fluorouracil, oxaliplatin, docetaxel), Oxaliplatin: Eloxatin, Docetaxel: Taxotere
McGill University
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
06/15
06/15
NCT01936974: (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Terminated
2
7
US
Gemcitabine, Gemzar, Bevacizumab, Avastin, Carboplatin, Paraplatin, Cisplatin, Platinol, Oxaliplatin, Eloxatin
Western Regional Medical Center
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
08/15
08/15
NCT01206049 / 2010-020385-13: Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

Completed
2
88
Europe
Gemcitabine, Oxaliplatin, Capecitabine, Panitumumab, Bevacizumab
Vejle Hospital
Cholangiocarcinoma
03/16
03/16
NCT01558869: Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

Completed
2
37
RoW
Capecitabine, Xeloda, Oxaliplatin, Irinotecan
The University of Hong Kong
Pancreatic Adenocarcinoma
12/16
12/16
NCT02195180 / 2013-004262-34: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

Completed
2
141
Europe
ERY001, L asparaginase encapsulated in erythrocytes, Gemcitabine, 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
ERYtech Pharma
Pancreatic Adenocarcinoma Metastatic
02/17
11/17
NCT01760252: Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol

Terminated
2
17
US
Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
Beth Israel Medical Center, St. Luke's-Roosevelt Hospital Center
Metastatic Pancreatic Adenocarcinoma
02/18
02/18
IXOGoo1, NCT01129310: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.

Completed
2
47
Canada
Irinotecan-Capecitabine-Oxaliplatin, Camptosar; Xeloda; Eloxatin
AHS Cancer Control Alberta, Sanofi
Gastrointestinal Neoplasm, Gastric Adenocarcinoma
05/18
05/18
NCT00732745: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Checkmark
Apr 2013 - Apr 2013: 
Terminated
1/2
9
US
docetaxel, oxaliplatin, vandetanib, placebo
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
06/10
 
EOXP, NCT00667420: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

Terminated
1/2
17
US
panitumumab, epirubicin, oxaliplatin, xeloda
Massachusetts General Hospital
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
06/11
06/14
NCT00374985: Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction

Completed
1/2
25
Europe
Docetaxel, Oxaliplatin, Radiotherapy
Johannes Gutenberg University Mainz
Esophageal Neoplasms, Stomach Neoplasms
09/13
09/13
NCT02048540: Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell

Completed
1/2
86
RoW
Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy
Chinese PLA General Hospital
Locally Advanced Gastric Carcinoma
12/13
12/13
NCT00526110: Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Completed
1/2
98
US
5-Fluorouracil, 5-FU, Adrucil, Efudex, Docetaxel, Taxotere, Oxaliplatin, Eloxatin
M.D. Anderson Cancer Center, Sanofi-Synthelabo
Gastrointestinal Diseases
06/15
06/15
NCT01415713: The Study of Metastatic Pancreatic Adenocarcinoma

Completed
1/2
73
RoW
S-1,Leucovorin,Oxaliplatin,Gemcitabine, G-CSF
National Health Research Institutes, Taiwan, National Taiwan University Hospital, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital
Metastatic Pancreatic Adenocarcinoma
04/16
04/16

Download Options